Extended Data Fig. 1: High level of PUS7 expression correlates with poor prognosis in GBM patients.
From: Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis
(a) The expression of PUS7 in all glioma patients stratified by the IDH mutation status and 1p19q chromosome co-deletion status from the CGGA dataset (n = 182 IDH mut 1p19q codel patients, n = 315 IDH mut 1p19q noncodel patients, n = 392 IDH WT patients). (b) The expressions of PUS7 in GBM patients stratified by IDH mutation status or GCIMP status from the CGGA (n = 90 Mut patients and n = 288 WT patients), TCGA (n = 8 Mut patients and n = 142 WT patients), Gravendeel (n = 33 Mut patients and n = 95 WT patients), and Rembrandt (n = 11 GCIMP patients and n = 208 Non-GCIMP patients) datasets. (c-f)Kaplan-Meier survival curves with log-rank analysis to assess the correlation between PUS7 expression and overall survival of IDH WT GBM patients in the CGGA dataset (c), TCGA dataset (e), and Gravendeel dataset (f) or non GCIMP GBM patients in the REMBRANDT dataset (d). (g) The expression of SOX2 and PUS7 in GBM patients and in non-tumor control samples in GBM tissue microarray analyzed by immunohistochemistry (IHC). Scale bar: 10 µm. (h) Quantification of the expression level of PUS7 in GBM patients and in non-tumor control samples analyzed by IHC. n = 34 individuals for GBM patients and 5 individuals for non-tumor control group. Error bars represent SD of the mean for panels a and b. Error bars represent SE of the mean for panel h. Two-tailed Student’s t test for panels a and b (ns: not statistically significant. p = 0.2844 for CGGA, p = 0.1533 for Gravendeel, and p = 0.1095 for Rembrandt). **p < 0.01 (p = 0.002) by one-tailed Student’s t-test for panel h.
